CRTX Cortexyme, Inc. Stock Quote

CRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.96	Insider Own	2.80%	Shs Outstand	30.13M	Perf Week	-1.79%
Market Cap	98.90M	Forward P/E	-	EPS next Y	-1.95	Insider Trans	0.00%	Shs Float	22.43M	Perf Month	-19.90%
Income	-88.50M	PEG	-	EPS next Q	-0.55	Inst Own	65.30%	Short Float	25.57%	Perf Quarter	-30.23%
Sales	-	P/S	-	EPS this Y	-14.90%	Inst Trans	2.97%	Short Ratio	12.69	Perf Half Y	-76.43%
Book/sh	3.53	P/B	0.93	EPS next Y	10.60%	ROA	-63.40%	Target Price	50.79	Perf Year	-90.93%
Cash/sh	3.06	P/C	1.08	EPS next 5Y	18.30%	ROE	-70.80%	52W Range	3.00 - 121.98	Perf YTD	-73.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.32%	Beta	-
Dividend %	-	Quick Ratio	9.90	Sales past 5Y	-	Gross Margin	-	52W Low	9.00%	ATR	0.36
Employees	55	Current Ratio	9.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.01	Volatility	9.83% 9.80%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	8.10%	Profit Margin	-	Rel Volume	0.73	Prev Close	3.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	451.81K	Price	3.27
Recom	2.90	SMA20	-8.25%	SMA50	-30.71%	SMA200	-89.50%	Volume	73,668	Change	-0.91%

Jan-28-22

Downgrade

Canaccord Genuity

Buy → Hold

$75 → $12

Jan-27-22

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Oct-27-21

Downgrade

BofA Securities

Neutral → Underperform

$58 → $15

Apr-26-21

Resumed

Credit Suisse

Underperform

$14

Feb-17-21

Downgrade

Jefferies

Buy → Hold

$59 → $34

Dec-11-20

Initiated

Citigroup

Sell

$20

Jun-24-20

Initiated

H.C. Wainwright

Buy

$76

Jun-02-20

Initiated

Jefferies

Buy

$59

Jun-03-19

Initiated

JMP Securities

Mkt Outperform

$53

Jun-03-19

Initiated

Credit Suisse

Underperform

$14

Jun-03-19

Initiated

Canaccord Genuity

Buy

$42

Jun-03-19

Initiated

BofA/Merrill

Neutral

$28

May-20-22 08:01AM	Cortexyme Appoints Dr. Philip Low to Its Board of Directors Business Wire
08:00AM	Cortexyme Successfully Completes Acquisition of Novosteo Business Wire
May-12-22 08:00AM	Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases Business Wire +7.01%
May-10-22 08:00AM	Cortexyme Announces Agreement to Acquire Novosteo Business Wire +13.41%
May-06-22 11:19AM	Is Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans? Simply Wall St.
May-03-22 09:56AM	Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves Benzinga
Mar-21-22 08:00AM	Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimers Population Business Wire
Mar-15-22 08:00AM	Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors Business Wire +7.93%
Mar-14-22 08:00AM	Cortexyme to Present New GAIN Trial Data at AD/PD 2022 Business Wire
Mar-09-22 08:00AM	Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders Business Wire
Mar-08-22 11:27AM	Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis Benzinga +8.24%
08:00AM	Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588 Business Wire
Feb-24-22 03:49PM	Short Sellers Were Right About These 10 Stocks Insider Monkey +6.22%
Feb-18-22 10:00AM	Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks Zacks -5.07%
Feb-03-22 03:03PM	Alzheimer's drug company to cut workforce in half, pay off exiting execs American City Business Journals -8.60%
Feb-02-22 10:00AM	After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX) Zacks -9.81%
Feb-01-22 05:16PM	After Alzheimer's drug flop, Peninsula biotech's founding execs exit American City Business Journals +12.34%
11:36AM	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI InvestorPlace
09:38AM	Atlas Capital Advisors Llc Buys Vanguard Short-Term Bond ETF, Fidelity MSCI Consumer ... GuruFocus.com
08:01AM	Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones Business Wire
08:00AM	Cortexyme Announces Change in Executive Leadership Team Business Wire
Jan-26-22 01:25PM	Why Cortexyme's Stock Is Crashing Today Motley Fool -31.46%
09:13AM	Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND Benzinga
08:00AM	Cortexyme Announces Clinical Hold on Atuzaginstats Investigational New Drug Application Business Wire
Jan-25-22 05:38PM	Burleson & Company, LLC Buys Block Inc, ARK Innovation ETF, Twitter Inc, Sells Airbnb Inc, ... GuruFocus.com
Jan-12-22 10:00AM	Why Cortexyme Stock Imploded in 2021 Motley Fool -5.07%
Jan-07-22 03:21PM	3 Most-Shorted Stocks at 52-Week Lows to Buy InvestorPlace
Jan-04-22 05:03AM	Do Institutions Own Cortexyme, Inc. (NASDAQ:CRTX) Shares? Simply Wall St.
Dec-17-21 01:50PM	The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 InvestorPlace
Dec-09-21 10:00AM	2 Short-Squeeze Candidates That Could Go Parabolic Soon Motley Fool -7.46%
Dec-01-21 09:01AM	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock? Zacks +6.92%
Nov-23-21 08:00AM	Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th Business Wire
Nov-11-21 04:08PM	Cassava And Cortexyme Diverge Why One Alzheimer's Stock Is 'Back On Track' Investor's Business Daily -7.43%
12:54PM	Why Are Cortexyme Shares Falling Today? Benzinga
11:30AM	Cortexymes Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimers Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021 Business Wire
10:08AM	Cortexyme Stock Falls After Presenting More Data From Alzheimer's Trial Investing.com
Nov-05-21 08:16AM	Possible turnaround for Cortexyme, Inc. (NASDAQ:CRTX) insiders, still down US$1.8m after a US$3.5m shopping spree Simply Wall St.
Nov-04-21 08:00AM	Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th Business Wire
04:33AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX PR Newswire
02:39AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX PR Newswire
Nov-03-21 11:15AM	Cortexyme, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire -5.77%
Nov-01-21 03:21PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX GlobeNewswire +7.65%
Oct-29-21 06:23PM	Cortexyme Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Cortexyme, Inc. GlobeNewswire -7.43%
05:08PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX Newsfile
Oct-28-21 10:00AM	Down 76%: Is Cortexyme Stock a Bargain? Motley Fool +5.55%
05:25AM	Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors Motley Fool
04:50AM	64 Biggest Movers From Yesterday Benzinga
Oct-27-21 10:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX ACCESSWIRE -76.58%
04:05PM	Cortexyme Says There's A Caveat In Its Missed Alzheimer's Test But Shares Crash Investor's Business Daily
02:40PM	Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge Benzinga
01:55PM	Why Cortexyme Shares Are Falling Benzinga
12:43PM	Here's Why Cortexyme Is Imploding on Wednesday Motley Fool
12:14PM	Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher Benzinga
12:00PM	44 Stocks Moving In Wednesday's Mid-Day Session Benzinga
12:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Cortexyme, Inc. (CRTX) Investigation ACCESSWIRE
11:18AM	Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value American City Business Journals
10:21AM	Mid-Morning Market Update: Markets Rise; Coca-Cola Tops Q3 Views Benzinga
10:20AM	Cortexyme's stock tumbles on failed clinical trial for Alzheimer's drug MarketWatch
07:09AM	28 Stocks Moving in Wednesday's Pre-Market Session Benzinga
Oct-26-21 04:01PM	Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimers Disease Progression Business Wire
04:00PM	Cortexyme's Alzheimer's treatment fails to meet main goals in study Reuters
Oct-21-21 11:00AM	Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market Investor's Business Daily
Oct-08-21 11:57AM	Notable Cortexyme Insider Trades $760K In Company Stock Benzinga
Sep-27-21 08:00AM	Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimers Disease at CTAD 2021 Business Wire
Sep-08-21 08:00AM	Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 Business Wire
Sep-07-21 08:00AM	Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th Business Wire
Aug-25-21 08:00AM	Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimers Disease at Annual Biomarkers for Alzheimers Disease Summit Business Wire
Aug-18-21 08:00AM	Cortexyme to Present at Annual Biomarkers for Alzheimers Disease Summit Business Wire
Aug-09-21 08:00AM	Cortexyme Provides Business Update and Reports Second Quarter 2021 Results Business Wire +47.32%
Aug-07-21 05:29AM	Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth Simply Wall St.
Aug-04-21 08:00AM	Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th Business Wire +10.83%
Jul-26-21 09:05AM	Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimers Disease at AAIC 2021 Business Wire -7.26%
Jul-23-21 08:00AM	Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection Business Wire
Jul-22-21 08:00AM	Cortexyme to Present New Data at AAIC 2021 Business Wire +5.41%
Jul-21-21 08:00AM	Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 Business Wire +5.92%
Jul-19-21 08:00AM	Cortexyme to Host Symposium at AAIC 2021 Business Wire
Jul-08-21 08:00AM	Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat Business Wire +5.08%
Jun-13-21 02:20PM	Hedge Funds Are Dumping Cortexyme, Inc. (CRTX) Insider Monkey
Jun-01-21 08:00AM	Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Business Wire
May-26-21 08:00AM	Cortexyme to Present at Investor Conferences in June 2021 Business Wire +12.99%
May-10-21 08:00AM	Cortexyme Provides Business Update and Reports First Quarter 2021 Results Business Wire -9.81%
May-09-21 04:13AM	How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares? Simply Wall St.
May-04-21 08:00AM	Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 Business Wire -7.96%
Mar-25-21 08:00AM	Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 Business Wire
Mar-21-21 09:52PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-18-21 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire -5.33%
Mar-16-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Mar-12-21 06:15AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Mar-10-21 08:00AM	Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 Business Wire +7.29%
Mar-09-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE +9.07%
Mar-08-21 08:00AM	Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimers Disease Data Presentation Business Wire
Mar-07-21 05:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-03-21 03:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Feb-22-21 01:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Feb-20-21 07:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Feb-18-21 09:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
04:45PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Cortexyme, Inc. (CRTX) Investigation ACCESSWIRE
Feb-17-21 11:38AM	The Bottom Is in for These 2 Stocks? Analysts Say Buy TipRanks
Feb-16-21 08:52AM	Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease Benzinga -35.29%
Feb-15-21 09:13PM	Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimers Disease Business Wire

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynch Casey	Chief Executive Officer	Nov 18	Option Exercise	0.46	60,000	27,600	109,895	Nov 19 08:58 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Nov 16	Option Exercise	2.23	30,000	66,900	90,000	Nov 16 08:17 PM
Dominy Stephen S.	Chief Scientific Officer	Nov 12	Buy	14.40	763	10,987	1,217,086	Nov 12 06:47 PM
McLoughlin Margaret	Director	Oct 08	Option Exercise	17.00	1,000	17,000	1,000	Oct 12 05:48 PM
McLoughlin Margaret	Director	Oct 08	Sale	88.93	1,000	88,930	0	Oct 12 05:48 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Oct 05	Option Exercise	54.85	4,963	272,221	64,963	Oct 07 06:24 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Oct 05	Sale	98.50	4,963	488,856	60,000	Oct 07 06:24 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 17	Option Exercise	2.23	30,000	66,900	60,000	Aug 18 05:25 PM
McLoughlin Margaret	Director	Aug 16	Option Exercise	17.00	6,000	102,000	6,000	Aug 18 05:30 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 16	Option Exercise	2.23	22,000	49,060	52,000	Aug 18 05:25 PM
McLoughlin Margaret	Director	Aug 16	Sale	95.44	6,000	572,644	0	Aug 18 05:30 PM
LOWE CHRISTOPHER P.	COO & Chief Financial Officer	Aug 16	Sale	95.31	22,000	2,096,779	30,000	Aug 18 05:25 PM
Detke Michael J.	Chief Medical Officer	Aug 10	Option Exercise	2.23	10,000	22,300	10,000	Aug 12 05:37 PM
Detke Michael J.	Chief Medical Officer	Aug 10	Sale	100.00	10,000	1,000,000	0	Aug 12 05:37 PM
Detke Michael J.	Chief Medical Officer	Jul 07	Option Exercise	2.23	17,400	38,802	17,400	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 07	Sale	55.20	17,400	960,549	0	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Option Exercise	2.23	12,600	28,098	40,861	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Sale	53.54	40,861	2,187,623	0	Jul 07 08:38 PM
McLoughlin Margaret	Director	Jun 28	Sale	55.15	550	30,332	0	Jun 29 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience